.svg){kind=small}
Apr-2026
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Canna Clinicals has demonstrated a noteworthy presence in the New York market, particularly within the Tincture & Sublingual category. The brand saw a significant jump in rankings from 11th place in January 2026 to 5th place in February, indicating a strong upward momentum. However, the following months saw a slight decline, with rankings moving to 7th in March and 8th in April. Despite these fluctuations, Canna Clinicals maintained a position within the top 10, which is a testament to its resilience and consumer appeal in this competitive category.
In terms of sales performance, Canna Clinicals experienced a robust increase in February, with sales reaching over $40,000, up from $18,102 in January. This surge aligns with their improved ranking during the same period. However, sales figures saw a decline in March and April, mirroring the slight drop in rankings. Such trends suggest that while Canna Clinicals has captured a significant portion of the market, maintaining consistent growth will require strategic efforts to address the fluctuations in consumer demand and market dynamics. The absence of Canna Clinicals from the top 30 in any other state or category may indicate potential areas for expansion or improvement.
Competitive Landscape
In the competitive landscape of the Tincture & Sublingual category in New York, Canna Clinicals has shown a dynamic shift in its market position from January to April 2026. Initially ranked 11th in January, Canna Clinicals made a significant leap to 5th place in February, reflecting a robust increase in sales performance. However, the brand experienced slight fluctuations, settling at 8th place by April. This volatility underscores the competitive pressure from brands like High Falls Canna New York, which consistently maintained a strong position within the top 10, and Ithaca Organics Cannabis Co., which improved its rank to 6th in April. Meanwhile, Harney Brothers Cannabis also demonstrated upward mobility, surpassing Canna Clinicals in April. Despite these challenges, Canna Clinicals' ability to achieve a top 5 ranking in February highlights its potential for growth amidst a competitive market environment.
Notable Products
In April 2026, Canna Clinicals' top-performing product was the CBD/THC 1:10 Max Strength Tincture, maintaining its consistent first-place ranking since January. The CBD/THC Unwind Tincture held steady in the second position from February through April, showing stable sales performance. The CBD/THC 1:1 Max Strength Capsules climbed to third place in April, up from fifth in February and March, with notable sales of 162 units. The CBD/THC Balance Tincture made a significant debut in April, securing the fourth rank. Lastly, the CBD/CBN/THC Sleep Tincture dropped to fifth place from its previous third-place ranking in March, indicating a decrease in sales momentum.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
